Health and Healthcare
Express Scripts Thumped by Short Seller Citron Research
Published:
Last Updated:
Around noon on Thursday, short-seller Citron Research offered some free advice to President-Elect Donald Trump: If Trump is serious about cutting prescription drug costs, go after Express Scripts Holdings Co. (NASDAQ: ESRX).
Express Scripts is the country’s largest pharmacy benefits manager (PBM), with over $101 billion in sales in 2015. The company’s biggest customer is health insurer Anthem Inc. (NYSE: ANTM), which filed suit against Express Scripts for around $15 billion in March of this year, claiming that the PBM violated the companies’ contract by charging too much and failing in its operation.
PBMs like Express Scripts negotiate drug prices from manufacturers and then offer to supply these drugs to health insurers like Anthem. To remain competitive in the insurance market, the insurers have to be able to compete on price. According to Anthem’s lawsuit, the insurer figures it is paying Express Scripts about $3 billion annually in excess charges.
Here’s the tweet from Citron that started the tumble in Express Scripts stock on Thursday:
https://twitter.com/CitronResearch/status/806921396391530496
A second tweet followed shortly:
https://twitter.com/CitronResearch/status/806922528455159808
Within half an hour Express Scripts’ stock had dropped about 10% to an intraday low of $68.00. By the end of the trading session the stock had recovered some to close at $70.75, down 6.7% for the day.
Express Scripts responded to a query from Investor’s Business Daily, saying, “We’re nothing like Philidor.” Specialty pharmacy Philidor is alleged to have changed orders in a ploy to increase reimbursements from insurers and boost sales for Valeant Pharmaceuticals International Inc. (NYSE: VRX). Express Scripts and CVS Health Corp. (NYSE: CVS) dropped Philidor from their networks last year.
CVS shares dropped 3% on Thursday, and the timing of the drop is a near carbon copy of the Express Scripts fall, and UnitedHealth Group Inc. (NYSE: UNH), which owns PBM OptumRx, dipped less than 0.1%. The other major U.S. PBM is Prime Therapeutics, a privately held company that serves Blue Cross/Blue Shield insurers around the country.
In after-hours trading Thursday, Express Scripts stock recovered about 1.8%, trading at $72.00. The stock’s 52-week range is $64.46 to $89.00. The consensus 12-month price target is $81.56, well above the $45 price target Citron suggests.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
